Phase 2 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People whose general health and ability to carry out daily activities meets a standard medical score of 2 or below on a scale used to measure cancer patients' wellbeing (confirm with trial site)
• People diagnosed with multiple myeloma that has returned or stopped responding to treatment, who have had at least one previous round of treatment, and who have at least one affected area of the body that a doctor can safely reach to take a small tissue sample
• People whose myeloma can be measured through specific blood or urine tests showing certain protein levels above set thresholds — or, in some cases, people without measurable disease may still be considered if scans or bone marrow tests confirm the diagnosis (confirm with trial site)
• People with a sufficient level of white blood cells called neutrophils (at least 1 x 10⁹/L)
• People with a sufficient platelet count (at least 75 x 10⁹/L)
• People with liver function test results within acceptable ranges as determined by blood tests
• People whose kidneys are working well enough, measured by an estimated clearance rate of at least 30 mL/min
• People whose heart is pumping blood effectively enough, with a heart pumping function of at least 40% as measured by a heart scan
• Women who could become pregnant must agree to use reliable contraception before starting and for at least 28 days after the last dose of one study drug, or 6 months after the last dose of the other study drug, and must tell their treating doctor immediately if pregnancy occurs or is suspected
• Men who have not had a vasectomy must agree to use contraception during treatment and for at least 28 days after the last dose of one study drug, or 3 months after the last dose of the other, and must not donate sperm during this time
• People who understand the nature of the trial and are willing to sign a written consent form before any study procedures begin

Who may not be able to join:

• People who have had a severe allergic reaction to certain related drugs, including thalidomide, lenalidomide, pomalidomide, carfilzomib, dexamethasone, or similar medicines, or who have any known reasons they cannot take these medicines according to prescribing guidelines
• People who have taken certain medicines that strongly affect how the body processes drugs, or certain stomach acid-reducing medicines (such as omeprazole or similar), within 2 weeks before starting the trial
• People who are unable or unwilling to take required blood clot prevention measures as outlined in the trial protocol
• People who have signs of bleeding from the gut or internal organs, or whose body does not respond to platelet transfusions
• People with other medical conditions that a doctor considers would put them at too much risk or interfere with their participation
• People with an active infection that required antibiotic or antiviral treatment within the past 14 days
• People who have had a different type of cancer in the past, unless they have been cancer-free for 3 or more years, or unless their previous cancer was a specific type of non-invasive skin, cervical, breast, bladder, or prostate cancer that was treated successfully with no known recurrence (confirm with trial site)
• People currently receiving other treatments for myeloma — though some supportive medications, such as bone-strengthening drugs and low-dose steroids at a stable dose for at least 7 days, may be permitted (confirm with trial site)
• People who are pregnant or breastfeeding
• People with serious mental health conditions, active alcohol dependency, or drug addiction that could interfere with follow-up care
• People with a known active HIV, hepatitis B, or hepatitis C infection, or a known history of HIV infection
• People diagnosed with a condition called systemic amyloidosis or POEMS syndrome (a rare condition involving abnormal plasma cells affecting multiple body systems)
• People who have had a stem cell transplant within the 12 weeks before joining the trial
• People who have received radiation therapy within 14 days before the first treatment day, unless the area treated covered a very small portion of the bone marrow (5% or less)
• People who are known to be intolerant of steroid medicines
• People with serious uncontrolled health conditions, such as active infection, severe heart failure, unstable chest pain, serious irregular heartbeat, or mental health or social circumstances that would make it difficult to follow the trial requirements
• People whose myeloma stopped responding to carfilzomib during their most recent course of treatment
• People who have previously received the study drug mezigdomide
• People who cannot safely undergo a procedure involving light sedation
• People who are unwilling or unable to follow the requirements of the trial
• People who, in the treating doctor's opinion, are not suitable candidates for the study drug for any other reason

Important: Always verify eligibility with the trial site directly before applying.